Singapore, April 2 -- US-based NJ Bio, Inc., a leading provider of integrated drug discovery and development services and Japan's Ajinomoto Bio‑Pharma Services, a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients.

This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next‑generation antibody-drug conjugates (ADCs) and other targeted therapeutics.

Through the collaboration, NJ Bio will integrate the AJICAP™ platform...